Modality
Cell Therapy
MOA
PLK4i
Target
SOS1
Pathway
Lipid Met
Crohn'sMCC
Development Pipeline
Preclinical
~Jun 2018
→ ~Sep 2019
Phase 1
Dec 2019
→ Nov 2029
Phase 1Current
NCT05620663
1,635 pts·MCC
2019-12→2025-05·Completed
NCT03737334
831 pts·Crohn's
2023-10→2029-11·Active
2,466 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-05-2310mo agoPh2 Data· MCC
2029-11-133.6y awayPh2 Data· Crohn's
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Complet…
P1/2
Active
Catalysts
Ph2 Data
2025-05-23 · 10mo ago
MCC
Ph2 Data
2029-11-13 · 3.6y away
Crohn's
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05620663 | Phase 1/2 | MCC | Completed | 1635 | PASI75 |
| NCT03737334 | Phase 1/2 | Crohn's | Active | 831 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Fixaosocimab | TG Therapeutics | Phase 2/3 | SOS1 | |
| Zanurapivir | Immunocore | Phase 1 | SOS1 | |
| Liravorutinib | Biomea Fusion | Phase 1/2 | GPRC5D | |
| Rilurelsin | Dynavax | Phase 1/2 | SOS1 |